Berna AYGÜN, Ali KARAYAĞMURLU, Nur Seda Gülcü ÜSTÜN

Risperidone-induced fecal incontinence: A case report

Fecal incontinence is defined as the inability to postpone or control the defecation requirement until socially convenient. There are many effective factors in its etiology. Drugs used in the treatment are one of these etiologic factors. Risperidone is an atypical antipsychotic with an antagonistic effect on dopamine 2 (D2) and serotonin 2A (5-HT2A) receptors and shows an affinity for noradrenaline α1 and α2 receptors. Risperidone is an effective and safe agent used in children and adolescents with psychiatric disorders such as oppositional defiant disorder (ODD) and conduct disorder. Fecal incontinence is an uncommon side effect of risperidone use. This report presents a 13-year-old patient with attention deficit hyperactivity disorder and ODD who developed fecal incontinence after dose increase due to risperidone treatment. This case is presented because there is a low number of case reports on risperidone-induced fecal incontinence in the literature.

PDF

___

1. Gaitonde SA, Moreno JL, Shah UH, Glennon RA, Dukat M, González-Maeso J. Revised pharmacophore model for 5-HT2A receptor antagonists derived from the atypical antipsychotic agent risperidone. ACS Chem Neurosci 2019; 10:2318-2331.
2. Gerlach J. New antipsychotics: classification, efficacy, and adverse effects. Schizophr Bull 1991; 17:289-309.
3. Den Boer JA. Risperidone in the treatment of psychosis; a concise review. Acta Neuropsychiatr 1995; 7:84-94.
4. Accordino RE, Kidd C, Politte LC, Henry CA, McDougle CJ. Psychopharmacological interventions in autism spectrum disorder. Expert Opin Pharmacother 2016; 17:937-952.
5. Brovedani P, Masi G, Pfanner C. Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study. J Psychiatr Res 2013; 47:1007-1012.
6. Blader JC, Pliszka SR, Kafantaris V, Foley CA, Carlson GA, Crowell JA, et al. Stepped treatment for attention-deficit/hyperactivity disorder and aggressive behavior: A randomized, controlled trial of adjunctive risperidone, divalproex sodium, or placebo after stimulant medication optimization. J Am Acad Child Adolesc Psychiatry 2021; 60:236-251.
7. Chakrabarty T, Keramatian K, Yatham LN. Treatment of mixed features in bipolar disorder: an updated view. Curr Psychiatry Rep 2020; 22:15.
8. Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Lu CT, Chang WH. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 2006; 26:128-134.
9. Chopko TC, Lindsley CW. Classics in Chemical Neuroscience: Risperidone. ACS Chem Neurosci 2018; 9:1520-1529.
10. Dursun OB, Esin IS, Karayagmurlu A, Ogutlu H. Myasthenia gravis attack after oral risperidone treatment: A case report. Eurasian J Med 2018; 50:128-129.
11. Fleischhaker C, Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex C, et al. Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. J Child Adolesc Psychopharmacol 2006; 16:308-316.
12. Albrecht H, Hoffmann H. Encopresis in childhood. Nervenarzt 1950; 21:271-281. [Undetermined Language]
13. Burns C. Encopresis (incontinence of faeces) in Children. Br Med J 1941; 2:767-769.
14. Tang CS, Chou WJ, Cheng AT. Osmotic release oral system (OROS) Methylphenidate-induced double incontinence: a case report. Prim Care Companion J Clin Psychiatry 2010; 12:PCC.09l00870.
15. Yektas C, Cansiz MA, Tufan AE. Increased frequency of encopresis in a child diagnosed with attention deficit/hyperactivity disorder and encopresis after atomoxetine Use: A case report. Clin Neuropharmacol 2016; 39:212-213.
16. Cop E, Oner O, Oner P. Risperidone and double incontinence in a child with autism. J Child Adolesc Psychopharmacol 2011; 21:647- 648.
17. Herguner S, Mukaddes NM. Risperidone-induced double incontinence. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:1085-1086.
18. Kose S, Akin E, Cetin M. Adverse drug reactions and causality: The Turkish version of Naranjo adverse drug reactions probability scale. Psychiatry Clin Psychopharmacol 2017; 27:205-206.
19. Lundin F, Rousseau A, Kadowaki A. A case report. Risperidone induced fecal incontinence as a result of reduced anal sphincter tonus. Lakartidningen 2004; 101:4006-4008. [Swedish]